Lincoln Capital Corp’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Lincoln Capital Corp’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-37,280	Closed	-$127K	–	57
2018 Q3	$127K	Sell	37,280 -28,520	-43%	-$103K	0.11%	46
2018 Q2	$247K	Sell	65,800 -2,110	-3%	-$10.3K	0.23%	41
2018 Q1	$278K	Buy	67,910 +1,000	+1%	+$4.66K	0.26%	44
2017 Q4	$311K	Buy	66,910 +30,410	+83%	+$168K	0.27%	41
2017 Q3	$259K	Hold	36,500	–	–	0.23%	42
2017 Q2	$264K	Buy	36,500 +6,200	+20%	+$38.7K	0.23%	44
2017 Q1	$187K	Buy	30,300 +3,500	+13%	+$19.2K	0.17%	50
2016 Q4	$158K	Buy	+26,800	New	+$146K	0.15%	49

Lincoln Capital Corp's KERX Position: Q4 2018 in Review

Lincoln Capital Corp sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 37,280 shares — an estimated $127K sold.

Lincoln Capital Corp first reported a position in KERX in Q4 2016 and held it in 8 quarters. The position peaked at $311K in Q4 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

Lincoln Capital Corp reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
Lincoln Capital Corp sold 37,280 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $127K.
Lincoln Capital Corp first reported a position in Keryx Biopharmaceuticals Inc in Q4 2016 and held it in 8 quarters.
Lincoln Capital Corp's Keryx Biopharmaceuticals Inc position peaked at $311K in Q4 2017.
1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Lincoln Capital Corp's 13F filing for Q4 2018, filed 22 Jan 2019.